PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few da...

Full description

Bibliographic Details
Main Authors:	Cinquegrani, M. (Author), Di Pino, A. (Author), Ferrara, V. (Author), Gullo, A.L (Author), Imbalzano, E. (Author), Mandraffino, G. (Author), Morace, C. (Author), Piro, S. (Author), Purrello, F. (Author), Scicali, R. (Author), Scuruchi, M. (Author), Squadrito, G. (Author), Toscano, A. (Author)
Format:	Article
Language:	English
Published:	MDPI 2022
Subjects:	acetylsalicylic acid adult alirocumab apolipoprotein B arterial stiffness Article atherosclerosis atherosclerotic injury atorvastatin biochemical analysis body mass breathing pattern clopidogrel cohort analysis common carotid artery controlled study coronary artery atherosclerosis diabetes mellitus diastolic blood pressure dyslipidemia electrocardiogram enzyme linked immunosorbent assay evolocumab ezetimibe familial hypercholesterolemia female gene expression genetic analysis glucose blood level heart infarction hemoglobin A1c heterozygosity high density lipoprotein cholesterol human hypertension hypertransaminasemia low density lipoprotein cholesterol low density lipoprotein receptor major clinical study male mechanical vascular impairment metformin non insulin dependent diabetes mellitus PCSK9 PCSK9 inhibitor proprotein convertase 9 protein blood level protein function pulse wave velocity risk factor rosuvastatin single nucleotide polymorphism sulfonylurea systolic blood pressure triacylglycerol
Online Access:	View Fulltext in Publisher

Similar Items

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies
by: Ngan T Tran, et al.
Published: (2015-04-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

Asociation of PCSK9 with Low Density Lipoproteins (LDL) in the Regulation of LDL-Cholesterol Levels
by: Sarkar, Samantha Khadija
Published: (2015)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

The association of LDLR and PCSK9 variants with LDL-c levels in a black South African population in epidemiological transition / Tertia van Zyl
by: Van Zyl, Tertia
Published: (2016)

The association of LDLR and PCSK9 variants with LDL-c levels in a black South African population in epidemiological transition / Tertia van Zyl
by: Van Zyl, Tertia
Published: (2016)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
by: Giovanni Ciccarelli, et al.
Published: (2018-03-01)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
by: Sai Sahana Sundararaman, et al.
Published: (2021-07-01)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
by: Qidi Ying, et al.
Published: (2021-02-01)

PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases
by: V Z Lankin, et al.
Published: (2018-09-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

The impact of Niacin on PCSK9 levels in vervet monkeys (Chlorocebus aethiops)
by: Ngqaneka, Thobile
Published: (2021)

Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
by: Ajay K Shukla, et al.
Published: (2019-01-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

THE INVOLVEMENT PROPROTEIN CONVERTASE SUBTILISIN/KEXIN OF TYPE 9 IN THE PATHOGENESIS OF ATHEROSCLEROSIS (LITERATURE REVIEW)
by: A. M. Chaulin
Published: (2020-03-01)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
by: Ping Jin, et al.
Published: (2021-10-01)

The Regulation of PCSK9 Structure and Function Through Lipoprotein Interactions
by: Sarkar, Samantha Khadija
Published: (2019)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake[S]
by: Adri M. Galvan, et al.
Published: (2019-01-01)

Discovery of Flavonoids from Scutellaria baicalensis with Inhibitory Activity Against PCSK 9 Expression: Isolation, Synthesis and Their Biological Evaluation
by: Piseth Nhoek, et al.
Published: (2018-02-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol
by: Francine Sirois, et al.
Published: (2017-03-01)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
by: Tingting Li, et al.
Published: (2021-01-01)

PCSK9 is not secreted from mature differentiated intestinal cells
by: Moreau François, et al.
Published: (2021-01-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
by: José Seijas-Amigo, et al.
Published: (2021-05-01)

Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
by: Nathan D. Wong, et al.
Published: (2019-03-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017-11-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

LDL Receptor Pathway Regulation by miR-224 and miR-520d
by: Alessandro G. Salerno, et al.
Published: (2020-05-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)